Multiple VEGF family members are simultaneously expressed in ovarian cancer: A proposed model for bevacizumab resistance

Current Pharmaceutical Design

Volumn 18, Issue 25, 2012, Pages 3784-3792

  van der Bilt, Arne R M ^a   van der Zee, Ate G J ^a   de Vries, Elisabeth G E ^a   de Jong, Steven ^a   Timmer Bosscha, Hetty ^a   ten Hoor, Klaske A ^a   den Dunnen, Wilfred F A ^a   Hollema, Harry ^a   Reyners, Anna K L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bevacizumab resistance; Ovarian cancer; VEGF A; VEGF B; VEGF C; VEGF D

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; OMENTAL METASTASIS; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOCHEMISTRY; OVARIAN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867495882     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802002661     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM., et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Lohela M, Bry M, Tammela T, et al. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009; 21: 154-65.
3. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 5165-71.
4. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-6.
5. th annual meeting of the American Society of Clinical Oncology (ASCO), 2010.
6. th congress of the European Society for Medical Oncology (ESMO), 2010.
7. Laakkonen P, Waltari M, Holopainen T, et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 2007; 67: 593-9.
8. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454: 656-60.
9. De Graeff P, Hall J, Crijns AP, et al. Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Br J Cancer 2006; 95: 627-33.
10. Duncan TJ, Al-Attar A, Rolland P, et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 2008; 14: 3030-5.
11. Rudlowski C, Pickart AK, Fuhljahn C, et al. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 2006; 16: 183-9.
12. Bolat F, Gumurdulu D, Erkanli S, et al. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma. Pathol Res Pract 2008; 204: 379-87.
13. Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al. Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma. Int J Gynecol Cancer 2006; 16: 241-6.
14. Sönmezer M, Güngör M, Ensari A, Ortaç F. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor. Int J Gynecol Cancer 2004; 14: 82-8.
15. Brustmann H, Naudé S. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol Oncol 2002; 84: 47-52.
16. Raspollini MR, Castiglione F, Garbini F, et al. Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int J Surg Pathol 2005; 13: 135-42.
17. Hata K, Nakayama K, Fujiwaki R, et al. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol 2004; 93: 215-22.
18. Ueda M, Hung YC, Terai Y, et al. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin Cancer Res 2005; 11: 3225-32.
19. Nishida N, Yano H, Komai K, et al. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 2004; 101: 1364-74.
20. Yokoyama Y, Charnock-Jones DS, Licence D, et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 2003; 88: 237-44.
21. Shen GH, Ghazizadeh M, Kawanami O, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000; 83: 196-203.
22. Fan F, Samuel S, Gaur P, et al. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer 2011; 104: 1270-7.
23. Grau S, Thorsteinsdottir J, Von Baumgarten L, et al. Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. J Neurooncol 2011 Feb 11 [Epub ahead of print].
24. Raspollini MR, Amunni G, Villanucci A, et al. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 2004; 14: 815-23.
25. Secord AA, Darcy KM, Hutson A, et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2007; 106: 221-32.